Investigational New Drugs

, Volume 30, Issue 3, pp 1248–1256

Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells

  • David Davidson
  • Yannick Coulombe
  • Veronica L. Martinez-Marignac
  • Lilian Amrein
  • Jeremy Grenier
  • Keira Hodkinson
  • Jean-Yves Masson
  • Raquel Aloyz
  • Lawrence Panasci
Short Report

DOI: 10.1007/s10637-010-9626-9

Cite this article as:
Davidson, D., Coulombe, Y., Martinez-Marignac, V.L. et al. Invest New Drugs (2012) 30: 1248. doi:10.1007/s10637-010-9626-9

Summary

This study sought to measure the degree of synergy induced by specific small molecule inhibitors of DNA-PK [NU7026 and IC486241 (ICC)], a major component of the non-homologous end-joining (NHEJ) pathway, with SN38 or oxaliplatin. Synergy between the DNA damaging drugs and the DNA-PK inhibitors was assessed using the sulforhodamine-B assay (SRB). Effects of drug combinations on cell cycle and DNA-PK activity were determined using flow cytometry and western blot analysis. DNA damage was assessed via comet assay and quantification of γH2AX. The role of homologous recombination repair (HRR) was determined by nuclear Rad51 protein levels and a GFP reporter recombination assay. Significant reductions in the IC50 values of SN38 were observed at 5 and 10 μM of DNA-PK inhibitors. Moreover, at 1–2 μM (attainable concentrations with ICC in mice) these DNA-PKcs inhibitors demonstrated synergistic reductions in the IC50 of SN38. Flow cytometric data indicated that SN38 and SN38 in combination with DNA-PKcs inhibitors showed dramatic G2/M arrest at 24 h. Furthermore, reduced phosphorylation of DNA-PKcs and increased DNA damage were observed at this time point with SN38 in combination with DNA-PKcs inhibitors as compared to cells treated with SN38 alone. SN38 alone and in the presence of ICC increased nuclear Rad51 protein levels. Furthermore, inhibition of DNA-PKcs increased HRR suggesting that NHEJ is a negative regulator of HRR. These data indicate that small molecule inhibitors of DNA-PKcs dramatically enhance the efficacy of SN38 in colon cancer cell lines.

Keywords

DNA-PKDNA-damageDNA-repairNon-homologous end joiningHomologous recombinationBreast cancerAnthracyclinesDrug synergism

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • David Davidson
    • 1
  • Yannick Coulombe
    • 2
  • Veronica L. Martinez-Marignac
    • 1
  • Lilian Amrein
    • 1
  • Jeremy Grenier
    • 1
  • Keira Hodkinson
    • 1
  • Jean-Yves Masson
    • 2
  • Raquel Aloyz
    • 1
  • Lawrence Panasci
    • 1
  1. 1.Montreal Centre for Experimental Therapeutics in Cancer—Segal Cancer Center—Lady Davis Institute—Jewish General HospitalMcGill UniversityMontréalCanada
  2. 2.Genome Stability Laboratory, Laval University Cancer Research Centre, Hôtel-Dieu de Québec Research Centre (CHUQ)QuébecCanada